InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,282.72
(
-0.27%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.14
(
0.00%
)
Bitcoin
62,859.05
(
-0.55%
)
Post# of 253168
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120475
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 81047

Saturday, 07/25/2009 1:52:32 AM

Saturday, July 25, 2009 1:52:32 AM

Post# of 253168
Re: The New Battle Lines in HIV (MRK Isentress)

In addition to the drawback of being dosed BID in a qD world, Isentress is evidently uncompetitive with other first-line HIV drugs on price. According to this PR from the AIDS Healthcare Foundation (an advocacy group for AIDS patients), the yearly price of Isentress for self-pay patients is $12,900* (~$35/day). This is about 3x the price of other commonly used first-line agents and it is additive to the prices of the other two drugs first-line patients must take as part of a 3-drug cocktail:

http://finance.yahoo.com/news/AHF-Renews-Challenge-to-Merck-bw-3048813737.html?x=0&.v=1

*When reimbursed under the Ryan White program, the yearly price is $8,100.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up